Localized chemotherapy
The most common types of cancer therapies include surgery, radiation, chemotherapy and their combinations. In the past decades, new treatment regimens have been discovered and implemented in the clinic, to concurrently or successively complement the standard proce dures in cancer therapy, and provide patients with improved treatment outcomes with fewer side effects. Some of these clinical and inves tigational treatment methods include: anti angiogenesis therapy [1] [2] [3] , immunotherapy [4] [5] [6] , gene therapy [7] [8] [9] , bone marrow transplanta tion and peripheral blood stemcell transplan tation [10] [11] [12] . Owing to the complex nature of the molecular targets of these newer therapies and their relatively short history since clinical introduction, they are not as widely used as con , they are not as widely used as con ventional chemotherapy and are substantially more expensive.
Most cancer patients will receive some type of chemotherapy during their treatments in the form of adjuvant, neoadjuvant or palliative ther apy. Although the firstline chemotherapies have provided lifesaving treatments for numerous cancer patients, their potential life threatening side effects should not be overlooked. The most severe side effects of chemotherapy are mainly caused by the systemic toxicities of the anticancer drugs. Since the conventional che motherapy is administered intravenously via a catheter or via the oral route, the cytotoxic drug travels throughout the systemic circulation of the patient and accumulate in his or her healthy organs, such as the kidneys, heart and liver, which eventually causes organ toxicity over time.
One of the issues with infusion and oral chemo therapy is that the effective dose of con ventional cytotoxic agents is often greater than or close to the maximum tolerable dose in the patient, depending on his or her disease stage and health condition. Therefore, to minimize the systemic exposure of the highly toxic chem otherapeutic agents, alternative locoregional drugdelivery routes have been explored in both preclinical investigations and clinical trials. To date, several localized chemotherapies have been adapted into clinical practices, providing can cer patients with additional options of therapy with fewer side effects. In this review, localized chemotherapy methodologies will be described, which include isolated limb perfusion (ILP), iso lated limb infusion (ILI), heated intraperitoneal chemotherapy (HIPEC), intrapleural perfusion hyperthermo-chemotherapy (IPPHC), isolated hepatic perfusion chemotherapy (IHP), percu taneous hepatic perfusion (PHP), transarterial chemoembolization (TACE), brain chemo wafers and lymphatic chemotherapy. All world wide open trials of the aforementioned regional chemotherapies are summarized in Table 1 [201] . This review article provides a basic introduction to a variety of regional chemotherapies. More detailed demonstrations of each procedure and results of the corresponding clinical trials are summarized in review articles elsewhere [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies Conventional oral and intravenous chemotherapies permeate throughout the body, exposing healthy tissues to similar cytotoxic drug levels as tumors. This leads to significant dose-limiting toxicities that may prevent patients from receiving sufficient treatment to overcome cancers. Therefore, a number of locoregional drug-delivery strategies have been evaluated and implemented in preclinical studies, clinical trials and in practice, in the past decades to minimize systemic toxicities from chemotherapeutic agents and to improve treatment outcomes. Localized treatment is beneficial because many cancers, such as melanoma, peritoneal cancer and breast cancer, advance locally adjacent to the site of the primary tumors prior to their circulatory invasion. In this article, we will review the feasibility, safety and efficacy of multiple localized chemotherapies in clinical use and preclinical development.
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Isolated limb perfusion chemotherapy
Isolated limb perfusion was initially introduced in the clinic in 1958 by the American surgeons, Creech and Krementz, using an extracorporeal circuit for regional chemotherapy of extrem ity melanoma [27] . Initially, the ILP procedure was performed at room temperature, but this procedure was later modified by Stehlin to be performed as a hyperthermic perfusion at 41-43°C [28] , as hyperthermia may enhance the cytotoxicity of chemotherapeutics and fur ther improve response rates. ILP works by tem porarily isolating the arm or leg of the patient from the circulatory system using a tourniquet, and perfusing a highly concentrated anticancer agent, such as melphalan, for a short period of time. Typically, several temperature probes are inserted into the subcutaneous tissue of the patient to monitor his/her body temperature. For example, ILP of the leg is performed by perfus ing the anticancer drug melphalan through a catheter inserted into the iliac artery of the leg. Another catheter in the draining vein collects the blood and the melphalan solution is allowed to circulate for 1-2 h. A tourniquet secured at the base of the leg prevents the highly concentrated anticancer agent from entering the systemic circulation. The ILP allows 10-20fold higher [22] . A total of 832 patients were enrolled in the trial. At the end of the followup period (median duration of 6.4 years), it was found that patients who received ILP exhibited reduced occurrence of intransit metastases (control: 6.6% vs ILP: 3.3%) and regional lymph node involvement (control: 16.7% vs ILP: 1.6%). However, the rate of the occurrence of distant metastasis or overall survival was not statistically altered.
Melphalan was the first and most effective anticancer agent utilized in ILP. Owing to the short halflife (t degradation = 50 min, pH 7.4 and 37°C) and the severe toxicity of melphalan in local limb tissues, there have been a number of clinical trials investigating alternative chemo alternative chemo chemo therapeutic agents. One of the agents was cis platin, which appeared to be effective for the treatment of melanoma in preclinical studies. Thompson and Gianoutsos conducted a cispla tin pilot trial in patients with recurrent mela noma [29] . Unfortunately, cisplatin ILP failed to demonstrate either disease inhibition or improved tissue toxicity, compared with mel phalan therapy, in the majority of the patients. Another platinumbased cytotoxic agent, car boplatin, was also investigated in clinical trials. Although partial response was observed in some patients, severe local toxicities such as motor sensory neuropathy and edema were reported in all patients. The pharmacokinetic data dem onstrated extremely high drug concentration in the regional skin; hence, further evaluation of carboplatinrelated treatment regimens was not warranted [30] . To date, melphalan remains to be the most successful anticancer drug for ILP in the treatment of unresectable extremity melanoma and other malignancies that recur in a localized fashion.
Since melphalan became a commonly accepted treatment strategy, combination ther apies using melphalan and other anticancer agents were extensively investigated in the 1990s, with the goal of further improving the rate of response and survival. Of these clinical investi gations, the most successful regimen introduced TNFa into the standard melphalan treatment. Eggermont and Lienard simultaneously reported the improved efficacy of melphalan and TNFa combination chemotherapy in multicenter trials for the treatment of both melanoma and soft tissue sarcoma [31, 32] . To explore the underlying mechanism that leads to the synergistic effect between melphalan and TNFa, a number of studies were conducted using animal xenograft models. Among the hypotheses of the synergism, de Wilt's explanation was widely accepted, in which he and his coworkers discovered that the addition of TNFa resulted in a sixfold increase of melphalan tumor accumulation in a rat model. Hence, it was not surprising that the combination therapy increased the inhibi the inhibi inhibi tion of tumor progression relative to melphalan treatment alone [33] . In an ILP trial with melpha lan and TNFa conducted by the US National Cancer Institute, 4 mg TNFa was reported as a safe and effective dose for treating intransit melanoma metastases of the extremities [34] .
Strategies for localized chemotherapy, such as ILP, greatly reduce the systemic side effects of anticancer agents by confining the drug to the blood capillaries of the tumorbearing limb. Systemic toxicities of melphalan ILP were only observed when systemic leakage had occurred due to the incomplete isolation of the perfused artery. A clinical study of 438 melphalan ILPs was conducted by Klaase et al. to determine the incidence of systemic leakage and the signifi cant factors that caused the leakage [35] . Of all patients who received melphalan ILP, 12.6% exhibited systemic drug leakage of ≥1% of the administered drug; in addition, 6.2 and 1.4% of the patients had 5 and 10% systemic drug leak age, respectively. Since >90% of the melphalan was confined to the limb, the low amount of melphalan that leaked to the systemic circulation led to relatively mild sideeffects compared with systemic regimens, for example, transient bone marrow depression. The most significant fac tors associated with systemic leakage were deter mined to be the level of isolation, the diameter of the venous cannula and the extent of the ligation of the perfused iliac vein.
The emergence of the melphalan-TNFa combination in ILP led to the clinical evaluation of the side effects caused by TNFa systemic leakage. In a trial in the Netherlands, patients with recurrent melanoma received ILP with the combination of the two anticancer agents [36] . The pharmacokinetic data reported an 11.4 to 31.5fold increase in the systemic TNFa combination of chemotherapy and embolization treatment, in which an anticancer drug is directly administered to the diseased organ, usually the liver, via the artery that supplies blood to the organ; meanwhile, embolic materials, such as biodegradable nanoparticles, are co-administered to the organ to partially block the blood supply so that cancer cells are deprived from sufficient nutrients.
Lymphatic chemotherapy:
A locoregional treatment regimen for lymphatically metastatic cancers, in which an anticancer formulation is targeted to the lymphatic system. future science group concentration in patients who had drug leak age compared with patients without systemic leakage. Although the systemic concentration of TNFa was greatly altered, only mild side effects manifested, including: fever, nausea and grade I/II hepatotoxicity, which represented the common toxicities of ILP using melphalan alone. Their findings suggested that the combination of melphalan and TNFa did not cause increased systemic toxicities relative to melphalan treat ment alone; thus, the combination regimen was recommended to patients as a standard ILP procedure in Europe considering its improved efficacy. However, a randomized multicenter ILP trial conducted by the American College of Surgeons Oncology Group (ACOSOG) sug gested a conflicting finding; where two patients from the melphalan TNFa combination cohort underwent a lower extremity amputation owing to the druginduced side effects. The trial was terminated as a result of the lack of improvement of the melphalan-TNFa therapy over standard melphalan therapy alone [37] .
In addition to melanoma, ILP is also used as a regional therapy for softtissue sarcomas, which are malignancies of muscles. Wray et al. reported two Phase II trials of extremity sarcomas, in which doxorubicin-and melphalan-TNFa combination therapy were compared using ILP. The results suggested that the latter regimen exhibited higher efficacy and lower toxicity [38] . Deroose et al. analyzed over 122 patients treated with ILPs to identify the role of adjuvant radio therapy, in terms of recurrence rate of soft tissue sarcomas. All patients received surgical resection and ILP with melphalan TNFa combination therapy, 70% of whom also received adjuvant radiotherapy. During the median followup of 31 months, a comparison of the recurrence rate was made between radiotherapytreated and untreated patients; however, no significant benefits were observed with adjuvant radiother apy [39] . In addition, Bonvalot et al. conducted a trial in patients with locally advanced soft tissue sarcoma, in which the toxicity of TNFa was evaluated and a safe dose of 1 mg TNFa was determined in the combination treatment with melphalan using hyperthermic ILP [40] . Besides melphalan, 1 mg TNFa can also be used effec tively in combination with doxorubicin for treat ing soft tissue sarcoma. Mildtomoderate limb and systemic toxicities were observed, while no treatmentassociated mortality was reported with the doxorubicin-TNFa combination therapy [41] .
Isolated limb infusion chemotherapy
Although ILP demonstrated improved efficacy and survival rate in patients with melanoma, it is still a complex and invasive procedure. To develop a simpler yet effective alterna tive, Thompson and coworkers at the Sydney Melanoma Unit introduced the ILI technique to the clinic in the 1990s [42] . ILI is a lowflow ILP, in which catheters are percutaneously inserted into the axial artery and vein of the diseased limb. The solution of a cytotoxic agent, such as melphalan, is infused and circulated for 15 to 60 min. A tourniquet is applied at the base of the limb to prevent systemic drug leakage (FiguRe 1) [43] . Unlike ILP, surgery is no longer necessary for this procedure; thus, the patient recovers quickly after the treatment.
A number of clinical trials were conducted to evaluate the feasibility and efficacy of this newer procedure and compared it to ILP [42, [44] [45] [46] . Lindnér et al. reported a satisfactory response rate of 85% for patients with melanoma who were treated with ILI [47] . Of these patients, 41% had complete response and 44% had par tial response. The response rate is comparable to the reported effectiveness of ILP. Another ILI trial conducted by Thompson et al. also demon strated similar results, suggesting that ILI is a less invasive, but equivalently effective, alternative of ILP [42] . Fewer patients (32%) developed severe limb and systemic toxicities compared with the ones treated with ILP [48] . This is especially ben eficial for elderly patients who cannot tolerate the surgery involved in ILP or its associated side effects. Several recent trials of ILI suggested a slightly lower response rate than the earlier tri als; for instance, complete response rates of 31% and 24% were reported by Beasley et al. [49] and Barbour et al. [50] , respectively, in 2009. In sum mary, ILI may be associated with less morbidity although it has been discovered to be slightly less effective in some patient populations com pared with hyperthermic ILP. Another benefit of ILI may be the possibility to readily repeat the procedure over a relatively short period of time [51] . Further, similar to ILP, ILI could also be integrated with combination therapy, taking advantage of the improved effectiveness of newer chemotherapeutic agents [52, 53] .
Heated intraperitoneal chemotherapy
Intraperitoneal chemotherapy was developed by Sugarbaker et al. in the 1980s to treat peri toneal carcinomas, including gastric and color , including gastric and color including gastric and color ectal cancers, as well as cancers that originated future science group elsewhere in the body, but have metastasized to the surface or interior of the peritoneal cav ity [54] . In HIPEC, a heated, high dose of an anticancer drug is circulated for a short period of time through the peritoneal cavity (FiguRe 2). HIPEC is often used as an adjuvant therapy after complete resection of the primary malignancies, to eradicate the residual disease at the site of the tumor. Some commonly used chemothera peutics, their dosages and durations of perfusion are summarized in Table 2 [23, [55] [56] [57] [58] [59] [60] [61] [62] [63] .
A clinical trial of patients with GI carcinoma reported the advantageous pharmacokinetics of HIPEC, in which the median AUC ratios Reproduced with permission from [43] .
Key Term
Cytoreduction: Also called debulking, which is an aggressive surgical procedure to remove a tumor mass as well as any surrounding tissues that may be susceptible to micro-and nano-metastases.
future science group of intraperitoneal/intravenous were determined to be 117 and 22 for 5fluorouracil (FU) and mitomycin C chemotherapy, respectively [54] . To justify the addition of HIPEC to the standard procedures of peritoneal cancer therapy, clini cal trials were conducted to compare the treat ment outcome of surgery alone to the combina tion regimen of HIPEC and complete resection in patients with advanced gastric carcinomas. In a clinical trial in Japan, 141 patients with advanced gastric cancer along with invasion were registered, 71 were treated with HIPEC using 5FU after complete gastric resection, and the remainder received surgery alone [64] . The results revealed a greatly reduced peritoneal recurrence rate over the 7year followup period (27 vs 47%, p = 0.0000847), and improved 2, 4 and 8year survival rates in the HIPEC cohort.
Besides 5FU and mitomycin C, other anti cancer agents have also been investigated for HIPEC. One of these investigational can didates for HIPEC is oxaliplatin, which is a platinumbased anticancer agent often used in the intravenous treatment of colorectal can cer. Elias et al. conducted a Phase II study of oxaliplatin in patients with advanced colorectal cancer in France [65] . They reported a prolonged 3year survival rate of 65%, with 68% of the living patients being free of peritoneal recur rence at the conclusion of the followup period (18.3-49.6 months).
Many latestage cancer patients with unre sectable tumors that cannot be effectively treated with available therapies receive pallia with available therapies receive pallia receive pallia receive pallia tive surgery preceding systemic chemotherapy to relieve diseaseassociated pain and improve their qualityoflife. Verwaal et al. conducted a randomized trial in the Netherlands to compare HIPEC of 5FUleucovorin in combination with aggressive cytoreduction surgery to the standard treatment regimen of palliative surgery followed by systemic chemotherapy, in patients with peri toneal carcinomatosis from colorectal cancer [66] . Aggressive cytoreduction is the surgical removal of any detectable microscopic tumors or metasta ses, often by debriding of the intestine and other tissue surfaces within the peritoneal cavity, after the complete excision of the primary tumor. Verwaal et al. reported a prolonged median sur vival period of 22.3 months for patients who received the experimental therapy with HIPEC, compared with 12.6 months for patients who received the standard treatment. Further, a sig nificant improvement in survival was observed for patients with five or less metastatic lesions in the peritoneal cavity, relative to patients who had seven or more metastases at the time of the surgery. According to a consensus statement pub lished by Esquivel et al. in 2007 , HIPEC is usu ally recommended to patients who are eligible for complete cytoreduction, therefore patient selec tion may play a critical role in the outcome of the HIPEC procedure [67] .
Cytoreduction, also known as debulking, may reduce the rate of recurrence for some patient populations. It is not always recom mended, because the aggressive resection may result in the removal of surrounding noncan cerous tissues, causing severe complications and increased mortality. A clinical trial, conducted by Jacquet et al. evaluated the posttreatment complications and the major risk factors of the HIPEC-cytoreduction combination procedure in patients with peritoneal carcinomatosis from adenocarcinoma of the colon or appendix [68] . The major complications included: anastomotic Oxaliplatin (460 mg/m 2 ) 30 [55] Mitomycin C (35 mg/m 2 ) 90 [56] Mesothelioma Cisplatin (25 mg/m 2 /l) and mitomycin C (3.3 mg/m 2 /l) 60 [57] Cisplatin (45 mg/l) and doxorubicin (15 mg/l), 3.4-6 l 60-90 [58] Cisplatin (50 mg/m 2 ) and doxorubicin (15 mg/m 2 ) 90 [59] Gastric Cisplatin (120 mg) and mitomycin C (30 mg) 60-90
Oxaliplatin (360-460 mg/m 2 ) and irinotecan (100-200 mg/m 2 ) 30 [60] Mitomycin (30-50 mg/m 2 ) and cisplatin (50-100 mg/m 2 ) 60-120 [61] Cisplatin (75 mg/m 2 ) and doxorubicin (15 mg/m 2 ) 60 [62] future science group leaks, bowel perforations, bile leaks and pancre atitis, which resulted in a 35% morbidity rate and 5% mortality rate. The complications were believed to be associated with the extent of the surgery, the length of the operation and the temperature of the perfused chemotherapeutic agents [68, 69] . To investigate the role of hyper thermia in localized chemotherapy a trial was conducted in patients with colon cancer. The authors reported that both normothermic and hyperthermic intraperitoneal chemotherapies were clinically safe and feasible. Although the patients who received the heated chemotherapy showed a higher incidence of anastomotic leak age, it was caused by the extensive resection of the colon, as opposed to the hyperthermic conditions of the perfusate [70] .
Intrapleural perfusion hyperthermo-chemotherapy
Since the clinical success of melphalan ILP was recognized, other localized treatment strategies have been investigated over the past decades.
Intrapleural perfusion chemotherapy, a localized therapy for the treatment of pleural disseminated malignancies in the body cavity that surrounds the lungs, is one of these newer therapies devel oped in the 1990s. Presurgery, several temp erature probes are inserted into the intercostal pleura to monitor the temperature of the pleural cavity. During the IPPHC procedure, the pri mary malignancy is first excised; subsequently, an irrigation inlet catheter and a drainage outlet catheter are inserted into the pulmonary artery and the pulmonary vein, respectively, and a highly concentrated anticancer drug, such as cisplatin, is perfused for 1-2 h. To determine the efficacy of IPPHC, a num ber of clinical trials were undertaken in patients with metastatic cancers that had spread to the pleura [71] [72] [73] [74] . Matsuzaki et al. reported a trial conducted in Japan in which one cohort of patients received intrapleural perfusion of cis platin after the removal of the malignancies, and the other cohort was treated with surgery alone [71] . The median survival of the experi mental group was 2.3fold longer than the stan dard surgerytreated group (20 vs 6 months). In addition, advantageous pharmacokinetic profiles were seen, demonstrated by the increased local concentration of cisplatin in the pleural cavity, along with minimal observed clinical compli cations. A similar clinical study was conducted a few years later by the same institution to com pare the apoptotic status of the tumor tissue, pre and postIPPHC with cisplatin. An eight and postIPPHC with cisplatin. An eight and postIPPHC with cisplatin. An eight IPPHC with cisplatin. An eight IPPHC with cisplatin. An eight with cisplatin. An eight cisplatin. An eight fold increase in the number of the apoptotic can cer cells was detected immunochemically in the postperfusion tissues compared with the tumor tissues pretreatment [72] .
Although [73] . No severe complications were observed in the study. Future trials with more patients and a longer followup time may be warranted to deter warranted to deter to deter mine whether the new modality is superior to the previous regimen.
Cisplatin is the most commonly used anti isplatin is the most commonly used anti cancer agent for IPPHC, but mitomycin C is also a candidate for this procedure. To evaluate the effectiveness of IPPHC using a cisplatin and mitomycin C combination treatment, a clinical trial was undertaken in patients with malignant pleural disease in France in 2003 [74] . The 1 and 5year survival rates of 74 and 27%, respec rates of 74 and 27%, respec of 74 and 27%, respec , respec respec tively, were reported, over a followup period of approximately 7.5 years. This combination regimen appeared to be especially effective for patients with T1 ("Tumor involves sameside pleura of the chest wall, with or without focal involvement of the pleura on the outer side of lung.") or T2 ("Tumor involves sameside pleura of the chest wall with at least one of the following features: confluent tumor on the outer surface of the lung, involvement of the muscles of the dia phragm, or involvement of the lung tissue deeper to the mesothum covering the lung.") mesothe lioma [202] , indicated by a median survival of 41.3 months. Therefore, patient staging and selection play a significant role in the design of a successful clinical trial for locoregional therapy.
Isolated hepatic perfusion chemotherapy
Locoregional chemotherapy for the treatment of unresectable liver cancers was first developed by Ausman in 1961 as an isolated hepatic perfusion technique [75] ; which isolates the hepatic blood flow from the systemic circulation, and directs anticancer drugs through the hepatic artery and vein. Unresectable liver carcinoma and hepatic future science group metastases disseminated from colorectal can cer and ocular melanoma are especially lethal diseases with an average survival time of only several months despite aggressive treatment. IHP offers the advantage of circulating a highly concentrated anticancer drug solution through the tumorbearing liver. Since the maximum delivered dose is limited by the tolerance of only the liver, as opposed to the whole body, usually a much higher concentration of perfusate can be administered compared with intravenous chemotherapy. The most commonly used anti cancer drugs for IHP consist of mitomycin C, melphalan alone or a melphalan-TNFa com bination. At the beginning of an IHP procedure, a laparotomy is performed to locate the hepatic artery and vein for the insertion of the irrigation inlet catheter and the drainage outlet catheter. The gastroduodenal artery is cannulated for the insertion of the inlet catheter, and the retrohe of the inlet catheter, and the retrohe the inlet catheter, and the retrohe patic inferior vena cava is dissected to position the outlet catheter. A perfusion circuit with a roller pump, a heat exchanger and an oxygenator, is secured to perfuse the anticancer drug through the liver for an hour [76] .
To examine the efficacy of this new proce dure, Alexander et al. conducted a clinical trial of IHP using the melphalan and TNFa com bination in patients with unresectable primary or metastatic secondary liver cancers [77] . The patients received a 1 h hyperthermic perfusion of the melphalan and TNFa combination. Post treatment, 75% of the patients developed reversible hepatic toxicities. At the end of the median followup period of 15 months, 3% of the patients showed a complete response to the therapy, and 72% of the patients exhibited a par tial response. The findings suggested that the melphalan and TNFa combination therapy might be an effective and safe treatment regimen for patients with unresectable liver cancers.
Percutaneous hepatic perfusion
Whereas ILP requires only a small incision in the tumorbearing limb, IHP requires a laparot omy for veinal and arterial access, thus it is a highly invasive and risky procedure despite the other advantages offered. To minimize the sur gical invasion and reduce complications, the IHP technique was modified and adapted to a nonsurgical procedure known as PHP. PHP is a relatively noninvasive alternative to IHP, which delivers an anticancer drug to the liver at dramatically increased concentrations, with minimum systemic side effects. Owing to the greatly reduced side effects and elimination of surgery, this procedure can be performed four tosix times at 1 month intervals. During a PHP, an infusion catheter is inserted through the skin into the femoral artery and guided to the hepatic artery, and then a second catheter is inserted into the femoral vein on the other leg and guided to the inferior vena cava (FiguRe 3) [78] . After insertion, double balloons on each catheter are inflated to block the normal blood flow to com plete the organ isolation. Subsequently, an anti cancer drug is perfused through the liver for 30 min. At the end of the procedure, the balloons are deflated and the catheters are removed. To evaluate the feasibility and procedureassoci ated side effects of PHP, Ravikumar et al. car ried out a pilot study in patients with advanced primary or metastatic liver cancers [79] . Patients were treated with PHP of either doxorubicin or 5FU. In the doseescalation study, the dose limiting toxicity was determined to be leuco penia in patients who received the highest dos age of doxorubicin or 5FU. One of the benefits of PHP is that the procedure only requires an overnight hospital stay, and patients recovered quickly after the perfusion. A significant tumor Reproduced with permission from [78] .
future science group response (>95% reduction of tumor size) was observed in 9.5% of the patients. Since the size of the patient population was small (23 patients), further randomized trials will have to be con ducted to evaluate the efficacy and safety of PHP compared with IHP. Pingpank et al. evaluated the safety of melphalan PHP and determined the maximum tolerated dose to be 3 mg/kg in patients with unresectable liver cancers. The results indicated that melphalan PHP had lim ited toxicity and improved antitumor efficacy compared with hepatic arterial infusion of the drug in a Phase I trial [80] . The same group also conducted a Phase III randomized trial in 2010 to compare the hepatic progressionfree sur vival and the overall response rate in patients with liver cancers originated from metastatic melanoma, who were treated with either melpha lan PHP or the best standard of care. The results demonstrated a fourfold extension in the hepatic progressionfree survival of patients treated by PHP relative to patients treated with standard of care (245 vs 49 days; p<0.001). In addition, PHP significantly improved the overall response rate compared with standard of care (34.1% for PHP vs 2% for standard of care; p<0.001) [81] .
Transarterial chemoembolization
Transarterial chemoembolization is a localized chemotherapy strategy used for the treatment of unresectable primary or metastatic liver car cinomas. It was developed by French surgeons Doyon and coworkers in 1974 [82] . Similar to PHP, TACE is another nonsurgical approach to deliver anticancer agents to the liver via cath eters that are inserted into the femoral artery. Unlike PHP, a TACE procedure does not require the doubleballoon catheters. In the TACE pro cedure, drugencapsulated degradable starch microspheres, liposomes, or other drug-particle matrices are administered to the liver to deliver the anticancer drug in a sustainedrelease pat tern. These particulates embolize the branches of the hepatic artery; thus, tumor deposits are deprived of nutrients and oxygen (FiguRe 4) [83] . Similar to the other locoregional therapies, TACE is confined to the tumorbearing liver; hence, the systemic toxicities of the anticancer drug may be greatly reduced.
A nationwide clinical trial of TACE was undertaken in Japan to elucidate the impact of TACE on the survival of patients with unresect able hepatocellular carcinoma, which is the most common type of liver malignancy [84] . A total of 8510 patients were enrolled in the study, who received an emulsion of Lipiodol ® , a contrast agent for in vivo imaging, and chemotherapeu tic agents, such as cisplatin and doxorubicin, preceding the administration of gelatin sponge particles. Gelatin sponge particles are resorbable materials first introduced to the clinic in the mid 1960s in interventional radiology. The optimal size of the gelatin sponge particles is believed to be 500-1000 µm. After administration, they induce the formation of thrombus, causing occlusion of the small end arteries. In this trial, the median survival, 1year and 3year survival rates were determined to be 34 months, 82% and 47%, respectively. The mortality rate of treatmentrelated complications was determined to be 0.5%. Their results suggested that TACE may be a safe and feasible treatment modality, laying the foundation for further developments to improve treatment effectiveness. However, the superiority of TACE over conventional intrave nous chemotherapy remains controversial due to the mixed clinical results of its efficacy in treating liver cancers [85] [86] [87] .
Although TACE is an independent procedure, it can be performed in combination with other procedures, such as a percutaneous ethanol injec tion (PEI), to improve the treatment efficacy and overall survival. Allgaier et al. conducted a trial of TACE and PEI combination therapy, and they compared it with TACE or PEI alone in patients with inoperable hepatocellular carcinoma [88] . The TACE and PEI combination cohort had a median survival of 25 months; whereas, TACE and PEI monotherapy cohorts had median sur PEI monotherapy cohorts had median sur monotherapy cohorts had median sur median sur vival times of 8 and 18 months, respectively. Although TACEinvolved treatment modalities have shown some advantages over standard intra venous chemotherapy, the procedurerelated mor bidity and mortality rates, remain major issues. A clinical trial conducted by Poon et al. revealed overall treatment morbidities and mortalities of 23 and 4.3%, respectively, for patients with inoper able hepatocellular carcinoma [89] . The mortality rate was as high as 20% for patients with tumors greater than 10 cm at the time of the procedure or serum albumin concentrations ≤35 g/l before the TACE. Therefore, careful evaluation of prognos tic factors and patient selection are key factors in the design of successful TACE protocols.
In 2002, Camma et al. conducted a computer ized metaana lysis of randomized controlled trials of TACE conducted between 1980 and 2000 for unresectable hepatocellular carcinomas, to evalu ate whether the previously reported superiority of TACE is significant relative to other conservative future science group modalities [90] . The survival data from the fol lowing trials involving intrahepatic procedures: TACE, TAC (transarterial chemotherapy), and TAE (transarterial embolization) were com pared with the conventional intravenous chemo therapies. TAC and TAE are modified TACE procedures. With TAC, chemotherapeutic agents are administered without embolizing particles; whereas with TAE, particle based artery blocking materials are given without chemotherapeutic agents. The authors reported that TACE signifi . The authors reported that TACE signifi cantly prolonged the 2year survival rate com pared with standard intravenous chemotherapy for patients with unresectable hepatocellular car cinoma. However, TACE did not demonstrate significant benefits, in terms of efficacy, relative to TAE. Their findings were consistent with the controversial role of using chemotherapeutic agents in TACE, owing to the additional side effects that were caused by an anticancer drug. The data involved in the metaana lysis was gener ated from the trials of TACE using 5FU as the anticancer drug. Further ana lysis using data from trials involving other chemotherapeutic agents may be informative in elucidating the impact of TACE over other therapy modalities.
Brain chemo-wafers
Glioma is the most common type of brain can cer, affecting approximately 10,000-20,000 Americans annually. Depending on the status of disease progression, gliomas can be classified into lowgrade gliomas (nonanaplastic, good prognosis) and highgrade gliomas (anaplastic, poor prognosis). Conventional chemotherapy usually offers limited benefits for patients with highgrade gliomas; most patients still have a short survival period of less than a year. To improve the efficacy of chemotherapy, drug releasing wafer implants have been developed as a regional treatment strategy to treat residual brain malignancy after excision of the primary tumor (FiguRe 5). These biodegradable wafers are made of polymers, such as polyanhydrides, coated with chemotherapeutic agents, including carmustine, and placed in the resection cavity during surgery.
Westphal and coworkers reported a multicenter controlled trial of carmustine releasing wafers (Gliadel ® Wafer, Guilford Pharmaceuticals) in patients with malignant glio mas [91] . Of the 240 postsurgery patients, 50% received carmustine wafers and 50% received placebo wafers. Following the wafer implanta tion, all patients were given radiotherapy. During a longterm followup study, the 1, 2 and 3year survival rates of patients in the carmustine group were 59, 16 and 9%, respectively. In comparison, the 1, 2 and 3year survival rates of patients in the placebo group were 49, 8 and 2%, respec tively. Thus, an improvement in the survival rate was observed for the carmustine wafer cohort. Reproduced with permission from [83] .
future science group
To evaluate the benefit of Gliadel wafers for local disease control, a clinical trial was conducted in patients with a single brain metastasis. The brain metastases resulted from the metastasis of the following primary cancers: lung cancer (52%), melanoma (16%), breast cancer (12%) or renal carcinomas (12%). After craniotomy, all patients were implanted with a Gliadel wafer and underwent postoperative radiation therapy. During a followup study of 9 months, no patients had relapsed at the site of wafer implantation; 16% of patients developed recurrent disease else where in the brain; and 8% of patients developed distant metastasis in the spinal cord. The results suggested that carmustine polymer wafers may be a promising strategy for providing local disease control and increasing survival rate [92] .
Since the approval of the Gliadel wafer, it has become a favorable approach for delivering chemo therapy to the brain. To assess its safety and iden tify waferassociated morbidities, a large clinical trial spanning 10 years and involving 1013 patients with gliomas was reported by Attenello et al. Of all the patients, 288 received a Gliadel wafer and the remainder did not receive any implant. Morbidities were observed post surgery, they included: pulmo nary embolism, deepvein thrombosis, surgical site infection, cerebrospinal fluid leak, seizure, symp tomatic malignant edema and meningitis. None of the aforementioned side effects were specific to the wafer implantation, suggesting Gliadel may be a safe approach for local delivery of carmustine chemotherapy [93] .
Lymphatic chemotherapy
The lymphatic system is a part of our immune system. The immune system is responsible for collecting and removing interstitial fluid from tissues; transporting fatty acids and vitamins to the circulatory system; and carrying antigen presenting cells to the lymph nodes via the lymph fluid, when an immune response is simulated by an invading microorganism. The lymphatic sys tem is a unidirectional network that is comprised of lymph fluid (lymph), lymphatic capillaries that carry the lymph and connecting lymph nodes. The lymph originates from the interstitial fluid, travels through the lymph vessels and is filtered by the lymph nodes, before it ultimately returns to the circulatory system via the right or the left subclavian veins. Unlike the circulatory system, the lymphatic system is unidirectional and is regulated by a valve mechanism (FiguRe 6). The oneway valves are located in both afferent and efferent lymph vessels, and they move the lymph from one segment to another segment of a lymph vessel due to segmental contractions. In addition, lymph flows slowly, because the lymphatic sys tem lacks a 'pump', such as the heart, to force the fluids to circulate. Similar to blood capillar ies, lymph capillaries branch into every part of our body except for the brain; therefore, tumor cells may use the lymphatic system in their initial nonhematological spread.
When a primary tumor mass develops, it secretes lymphangiogenic cytokines that induce the formation of new lymph vessels [94] . The tumor cells invade the new lymph vessels and follow the lymph until entering the nearest drain ing lymph node, the sentinel lymph node, via the subcapsular sinus. The sentinel lymph node can trap the cancer cells, but if it does not successfully destroy the cancer cells, it may become the site of a secondary tumor and pass the tumor cells to the next draining lymph node. Ultimately, tumor cells may travel to the circulatory system and deposit in healthy organs resulting in the for mation of distant metastases (FiguRe 7) [95] . Since the lymphatic system plays a critical role in cancer metastasis, it has been recognized as a target for localized approaches to treat cancers that spread via the lymphatics, such as breast cancer, lung cancer and ovarian cancer, as well as head and neck cancer.
The subcutaneous tissues contain a rich sup ply of lymph capillaries, and so subcutaneous injections have become the most widely used route for delivering lymphatictargeted chemo therapeutic agents in preclinical trials. The fate 
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Nonhematological spread:
Cancer cells may disseminate from a primary tumor to other healthy organs via a noncirculatory route, such as a lymphatic route, in their initial metastasis.
future science group of subcutaneously injected materials depends on a variety of factors, including: size, charge and hydrophobicity. The optimal size range for lymphatic drainage is believed to be 10-100 nm. Molecules smaller than 10 nm mainly enter the systemic circulation through blood capil laries via diffusion; whereas, molecules larger than 100 nm have substantial local retention at the injection site. Therefore, molecules of 10-100 nm may be good candidates for subcu taneous injections for lymphatic drug delivery. Furthermore, neutral or anionic materials were shown to demonstrate better lymphatic uptake compared with cationic materials [96] . This is likely due to the enhanced macrophage uptake and the subsequent lymphatic drainage of the neutrally or negatively charged particles. The interior wall of the lymphatic lumen bears nega tive charges; thus, the charge repulsion between the wall of the lymph vessel and the surface of the Reproduced with permission from [95] .
future science group subcutaneously injected materials causes them to move faster towards the draining lymph nodes. Since most firstline cytotoxic drugs are small molecules, carriers that can deliver smallmole cule drug cargo to target the lymphatics are of great interest to drugdelivery scientists. The can didates in this category include a variety of bio degradable polymers [97] [98] [99] , liposomes [100] [101] [102] , micelles [103, 104] and nanoparticles [96, 105] . The therapeutic and imaging applications of these lymphatic platforms have been reviewed in detail by Xie et al. [106] . Subcutaneous administration of these drug loaded nanoformulations usually leads to enhanced accumulation and retention of the drug in the draining lymph nodes, in preclinical animal models. These conjugates also take advan tage of their controlled drug release properties to alter the pharmacokinetics of the anticancer drugs, by reducing the peak plasma concentra tion, as well as prolonging systemic retention. The modified pharmacokinetics may further translate into an improved safety profile, by reducing the C max associated systemic side effects of the drug. In addition, a number of xenograft models sug gest that subcutaneously injected carrierbased drug conjugates resulted in better treatment efficacy and survival compared with the conven tional intravenous chemotherapy. Although no lymphatic chemotherapies have yet entered the clinic, a number of intralymphatically delivered imaging agents have been used in the clinic for cancer staging and identification of the sentinel lymph node [107] [108] [109] [110] [111] .
Future perspective
Since the introduction of isolated limb per fusion chemotherapy into the clinic in the mid1950s for the treatment of melanoma, a variety of locoregional chemotherapy strate gies have been developed and adapted into clinical practices in past decades, including HIPEC, IHP and brain wafer chemotherapy, which are discussed in this article. These pro cedures have now become the standardofcare for patients with peritoneal cancer, unresect able liver cancer and gliomas. Such localized chemotherapy regimens usually offer improved local disease control and reduced systemic toxicity, compared with conventional chemo therapy, therefore, they hold great promise for cancer patients. Other less widely used regional chemotherapies that are not reviewed in this article include administration of chemothera peutics via pancreatic perfusion (pancreatic cancer) [112, 113] , celiac axis infusion (pancreatic cancer) [114, 115] , hypoxic abdominal stopflow perfusion (gastric cancers) [116, 117] and pelvic perfusion (advanced colorectal cancers) [118, 119] . Nevertheless, the absolute superiority of some of the newer techniques relative to infusion chemotherapy remains controversial in terms
Executive summary
Locoregional chemotherapy delivers anticancer drugs directly to the site of the malignancy, avoiding first-pass metabolism and minimizing systemic side effects; thus, this drug-delivery strategy has become a popular approach for local disease control.
Isolated limb perfusion chemotherapy is a localized approach to administer an anticancer drug to the artery of the limb of patients with localized melanoma. By applying a tourniquet at the root of the limb, it prevents cytotoxic agents from entering the circulatory system, therefore, minimizing systemic toxicities caused by the chemotherapeutic.
Heated intraperitoneal chemotherapy has become a popular strategy for treating peritoneal cancers after initial surgical resection. Heated chemotherapy further improves the efficacy of the locally administered anticancer drug.
Intrapleural perfusion hyperthermo-chemotherapy is primarily utilized for the treatment of pleural metastasis of cancers that originated from elsewhere in the body. It appears to be a safe alternative to intravenous infusion and provides improved local disease control.
Isolated hepatic perfusion chemotherapy takes advantage of the localized delivery of an anticancer drug to the liver, sparing the other healthy organs from exposure to the toxic chemotherapy; thus, perfusion chemotherapy may be performed multiple times within a short period of time.
Transarterial chemoembolization is a minimally invasive procedure, which does not require a surgery. An infusion catheter inlet is inserted into the femoral artery of the groin and guided to the liver. An anticancer drug and an embolic agent are co-administered into the liver. The rationale for including a biodegradable embolic agent is to partially block the blood supply of the tumor.
Gliadel wafer is so far the only US FDA-approved, chemotherapy-coated brain implant for gliomas. The wafer releases carmustine in a sustained-release pattern from the tumor cavity to the surrounding brain tissues. The polymer-based biodegradable wafer dissolves slowly over the course of three weeks, thus, no surgical procedures are required to remove the device after the drug has been released.
Lymphatic chemotherapy is a locoregional chemotherapy targeting the lymphatic system to where many cancers initially metastasize. Nanoparticle-based chemotherapies are often used to deliver anticancer drugs to tumor-draining lymph nodes and the surrounding lymph basin.
future science group of their improvement in patient survival rate. Furthermore, many localized chemothera pies often require more sophisticated surgical devices, such as the doubleballoon catheter in transarterial chemoembolization, making the widespread use of such procedures challeng ing. Moving forward, careful evaluation of the safety and procedureassociated morbid ity of localized drugdelivery strategies may lay the foundation of replacing intravenous chemotherapy with more effective, less toxic regional chemotherapy. 
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